2 januari 2020: Bronnen: verschillende studies

Afgelopen jaar werden verschillende studies gepresenteerd op ASCO en ESMO o.a. waarin combinatiebehandelingen met immuuntherapie met anti-PD medicijnen voor gevorderde nierkanker goede resultaten laten zien op de progressievrije overleving en op de overall overleving in percentages van tientallen procenten. Zie ook in gerelateerde artikelen.

Hier de studies die afgelopen jaar werden gepubliceerd, klik op de titels voor de studierapporten en abstracten:

  1. Choueiri TK, Powles T, Burotto M, et al. 696O_PR Nivolumab + cabozantinib vs sunitinib in first-line treatment for advanced renal cell carcinoma: First results from the randomized phase III CheckMate 9ER trial. Ann Oncol. 2020;31(suppl 4):S1157.
  2. Rini BI, Plimack ER, Stus V, et al; KEYNOTE-426 Investigators. Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1116-1127.
  3. Motzer RJ, Penkov K, Haanen J, et al. Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med. 2019;380(12):1103-1115.
  4. Motzer RJ, Rini BI, McDermott DF, et al; CheckMate 214 investigators. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial. Lancet Oncol. 2019;20(10):1370-1385.
  5. Pal S, Tsao C, Suarez C, et al. Cabozantinib (C) in combination with atezolizumab (A) as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): results from the COSMIC-021 study. Presented at ESMO Virtual Congress 2020. Accessed November 8, 2020.
  6. A study of atezolizumab in combination with cabozantinib compared to cabozantinib alone in participants with advanced renal cell carcinoma after immune checkpoint inhibitor treatment (CONTACT-03). NCT04338269. Updated October 14, 2020. Accessed November 8, 2020.
  7. Vogelzang NJ, Olsen MR, McFarlane JJ, et al. Safety and efficacy of nivolumab in patients with advanced non-clear cell renal cell carcinoma: results from the phase IIIb/IV CheckMate 374 study. Clin Genitourin Cancer. 2020 May 16. doi:10.1016/j.clgc.2020.05.006. Online ahead of print.
  8. Lee JL, Ziobro M, Gafanov R, et al. KEYNOTE-427 cohort B: first-line pembrolizumab (pembro) monotherapy for advanced non‒clear cell renal cell carcinoma (NCC-RCC). J Clin Oncol. 2019;37(suppl 15):4569.
  9. Rini BI, Motzer RJ, Powles T, et al. Atezolizumab plus bevacizumab versus sunitinib for patients with untreated metastatic renal cell carcinoma and sarcomatoid features: a prespecified subgroup analysis of the IMmotion151 clinical trial. Eur Urol. 2020 Jul 9. doi:10.1016/j.eururo.2020.06.021. Online ahead of print.
  10. Tannir NM, Signoretti S, Choueiri TK, et al. Efficacy and safety of nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma. Clin Cancer Res. 2020 Sep 1. doi:10.1158/1078-0432.CCR-20-2063. Online ahead of print.
  11. Randomized phase-II study of nivolumab plus ipilimumab vs. standard of care in untreated and advanced non-clear cell RCC (SUNIFORECAST). NCT03075423. Updated June 2, 2020. Accessed November 8, 2020.

Plaats een reactie ...

Reageer op "Combinatiebehandelingen met vormen van immuuntherapie en anti-PD medicijnen geven veelbelovende resultaten bij (gevorderde) nierkanker. Hier de belangrijkste studies van afgelopen jaar"


Gerelateerde artikelen
 

Gerelateerde artikelen

Specificiteit van het menselijk >> Immuuntherapie met pembrolizumab >> Cabozantinib toegevoegd aan >> Immuuncheckpointremmers nivolumab >> Clostridium butyricum (CBM >> Immuuntherapie met avelumab >> Combinatiebehandelingen met >> Immuuntherapie met combinatiebehandeling >> NLR meting - veranderende >> Immuuntherapie met Atezolizumab >>